85 filings
Page 3 of 5
8-K
w41blkj3zqss9lm
21 Sep 22
Regulation FD Disclosure
7:06am
8-K
ic7n md9d
15 Aug 22
Clene Reports Second Quarter 2022 Financial Results and Recent Operating Highlights
7:05am
8-K
omp6mx1e4841be3s4a2
21 Jul 22
Regulation FD Disclosure
4:03pm
8-K
p5z44z3w onu
14 Jul 22
Regulation FD Disclosure
7:20am
8-K
f6yui
1 Jun 22
Regulation FD Disclosure
7:08am
8-K
ymv0x xl7b
19 May 22
Clene Receives $3 Million Loan from State of Maryland to Support
4:07pm
8-K
cvo7nnwi6c6m
9 May 22
Clene Reports First Quarter 2022 Financial Results and Recent Operating Highlights
8:03am
8-K
qhjq4syt f0n
6 May 22
Submission of Matters to a Vote of Security Holders
4:12pm
8-K
qf3y6v8nq5c38si82zml
18 Apr 22
Regulation FD Disclosure
8:07am
8-K
r02exu0
14 Apr 22
Entry into a Material Definitive Agreement
4:02pm
8-K
jfe69fa
5 Apr 22
Regulation FD Disclosure
4:07pm
8-K
cj1wywj g49cshk
14 Mar 22
Interim results demonstrate approximately 70% decreased risk of death for participants who entered the RESCUE-ALS long-term open label extension
7:02am
8-K
4khgf91y
11 Mar 22
Clene Reports Full Year 2021 Financial Results and Recent Operating Highlights
7:04am
8-K
y4vbeirx3m3gnlenv
24 Feb 22
Clene Nanomedicine Presents Data from Two Phase 2 Multiple Sclerosis Trials at ACTRIMS Forum 2022
7:02am
8-K
0jhpk
15 Feb 22
Clene Nanomedicine Provides Clinical Program Update
7:01am
8-K
vt8e5b 673t
2 Feb 22
Clene Announces New Chief Financial Officer Morgan Brown
12:00am
8-K
qubgyb cc7wey0d
18 Jan 22
Clene Nanomedicine’s Second Asset, CNM-ZnAg, Completes 50% Patient Enrollment in COVID-19 Trial
7:00am
8-K
t2jm422ls21tcka47l15
17 Dec 21
Regulation FD Disclosure
12:00am
8-K
8myletalx7
14 Dec 21
Other Events
4:43pm
8-K
hu016ctu8cmctksa0
1 Dec 21
Clene Nanomedicine Presents Updated Data from RESCUE-ALS Phase 2 Study at 4th Annual ALS ONE Research Symposium
7:05am